Management Of Hematologic Malignancies

Hematologic malignancies were the first human cancers to be studied in depth at the molecular level, and recent years have seen important advances in treatment. This comprehensive reference book covers the full range of hematologic malignancies, including all subtypes of leukemias, lymphomas, and plasma cell dyscrasias. Authored by internationally known experts, each chapter emphasizes diagnostic work-up, staging, and therapeutic approaches. Up-to-date hematopathology, treatment, and outcomes data are presented in a way which is directly applicable to patient care. Highly illustrated with color images, graphs, flowcharts and treatment algorithms, the book is perfect for quick clinical reference as well as providing detailed reference lists for further study. With its authoritative and practical focus and visually stimulating presentation, this is a key text for hematology and oncology fellows, physicians, oncology nurses, physician assistants and other healthcare workers in the field of oncology.

Handbook of Hematologic Malignancies provides a unique, practical, and concise guide focused on the must-know points of diagnosis, prognosis, therapeutic management, and cutting edge clinical trial opportunities for each hematologic malignancy. With an ever-increasing growth of evidence and a significant expansion of available treatment options for patients with hematologic disease, remaining current and up-to-date can be extremely challenging for practicing clinicians. This comprehensive subspecialty handbook is designed and organized for the busy hematologist, hematologic oncologist, hematopathologist, and trainee in mind. Every chapter is richly illustrated with color figures and flow diagrams, and contains helpful tables on differential diagnosis, prognostic scoring systems and therapeutic options. A concise case-based review for testing pathologic diagnosis and clinical knowledge for each chapter is included for digital download online and in the e-book. Written by experienced clinicians at the world-renowned Moffitt Cancer Center in Tampa, Florida, as well as contributions from leading academicians throughout the country, this handbook is an essential resource for anyone diagnosing, treating, or managing patients with hematologic malignancy. KEY FEATURES: Contains clear prognostic and diagnostic tools (e.g., tables/flow diagrams/pathology images) with emphasis on key differential diagnoses and diagnostic dilemmas Easy to use treatment recommendations with bullet point format and key references. Discusses the future of patient management based on practice changing clinical trials Includes access to digitally downloadable case-based clinical scenarios and questions with high resolution pathology images linked to each individual chapter

More than 180 years since Thomas Hodgkin identified the first hematologic malignancy, nurses are still learning the best ways to treat patients with these complex cancers. Hematologic Malignancies in Adults gives you comprehensive information on treatments, complications, and toxicity management for your everyday practice. The book focuses on the management of disease-related manifestations and treatment-related side effects and toxicities. You'll find details on forms of hematologic malignancies, including leukemia and lymphoma, Hodgkin lymphoma, mature T-cell and NK-cell neoplasms, and multiple myeloma. Also included is a chapter on vascular access and a listing of drugs used in the treatment of hematologic malignancies. The management of patients with myeloid and lymphoid neoplasms is unique, complex, and vital to ensuring successful outcomes and improved quality of life. This book gives you every tool you need to keep pace with the advances in medicine and science as you trea

This issue of PET Clinics focuses on PET in the Management of Hematologic Malignancies and is edited by Drs. Abass Alavi (the Consulting Editor of PET Clinics), Gary Ulaner, Jakub Svoboda, and Lale Kostakoglu. Articles will include: PET-CR as a surrogate to replace PFS in assessment of efficacy of DLBCL treatments; PET-Derived Quantitative Metrics for Response and Prognosis; Evolving Role of PET Based Novel Quantitative Techniques in the Management of Hematological Malignancies; Critical Role of FDG/NaF imaging in Assessment of Skeletal Involvement in Patients with Multiple Myeloma; Response adapted treatment strategies in Hodgkin lymphoma using PET scans; FDG PET/CT as a staging tool in multiple myeloma; FDG PET/CT as a predictor of prognosis in multiple myeloma; PET/CT as a response evaluation tool in multiple myeloma; PET imaging in CLL and Richter’s transformation; Current Overview and Future Directions of PET for Hematologic Malignancies; and more!

The aim of Hematologic Malignancies: Methods and Techniques is to review those methods most useful for the diagnosis and subsequent mana- ment of hematologic malignancies. The scope of coverage is intentionally broad, ranging from routine procedures to highly sophisticated methods not currently offered by most clinical laboratories. The latter methods were selected especially to bring into focus recent advances in molecular biology that, since they provide us with strong tools for assessing the outcome of upcoming therapeutic modalities intent on disease eradication, are expected to impact the future diagnosis and management of these diseases. Thus, the c- mon thread among all chapters is clinical relevance, whether sanctioned by past experience or by the expectation that seemingly esoteric research techniques of today will prove clinically valuable in the future. Hematologic Malignancies: Methods and Techniques is primarily a compilation of methods presented in sufficient detail—by authors with extensive expertise in their field—to serve not only as a reference for seasoned research and clinical laboratory pers- nel, but also as a guide for the less experienced. Moreover, the contributing authors also discuss the pathophysiologic bases and the diagnostic usefulness that underscore each method’s clinical relevance. Thus, this volume should be also valuable to clinicians—especially hematologists, oncologists, and path- ogists—often bewildered by an ever increasing flow of new scientific inf- mation, the practical application of which is often either not clearly disclosed or difficult to discern.

Since the late 1960s, the survival rate in children and adolescents diagnosed with cancer has steadily improved, with a corresponding decline in the cancer-specific death rate. Although the improvements in survival are encouraging, they have come at the cost of acute, chronic, and late adverse effects precipitated by the toxicities associated with the individual or combined use of different types of treatment (e.g., surgery, radiation, chemotherapy). In some cases, the impairments resulting from cancer and its treatment are severe enough to qualify a child for U.S. Social Security Administration disability benefits. At the request of Social Security Administration, Childhood Cancer and Functional Impacts Across the Care Continuum provides current information and findings and conclusions regarding the diagnosis, treatment, and prognosis of selected childhood cancers, including different types of malignant solid tumors, and the effect of those cancers on childrenâ (TM)s health and functional capacity, including the relative levels of functional limitation typically associated with the cancers and their treatment. This report also provides a summary of selected treatments currently being studied in clinical trials and identifies any limitations on the availability of these treatments, such as whether treatments are available only in certain geographic areas.

This book is designed to assist practitioners in managing patients who present with difficult cases of the most common hematological malignancies. The scenarios covered are those that are likely to be encountered in patients with the various forms of Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and leukemia. In each of the three sections devoted to these malignancies, multiple cases are presented. The case discussions follow a standard format. A clinical description is followed by a pathological description documenting information relevant to diagnosis and by details of staging work-up, including images. The treatment options are then discussed at length, highlighting relevant literature for each option. Finally, the treatment delivered is identified and images of the planning technique/modality used are provided. This book will be an invaluable aid to decision making for radiation oncologists and will also be of interest for hematologists.

The book Advances in Hematologic Malignancies presents new knowledge of cellular disease processes, molecular pathology, and cytogenetic, epigenetic, and genomic changes that have influenced the current outlook toward hematological malignancies. This book provides a unique, practical, and concise guide that is focused on the must-know points of diagnosis, prognosis, therapeutic management, and cutting edge clinical trial opportunities for each hematologic malignancy. Advances in Hematologic Malignancies is designed and organized as an essential reference source for the hematologist, hematologic oncologist, hematopathologist, and trainee.